CU20150170A7 - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
CU20150170A7
CU20150170A7 CUP2015000170A CU20150170A CU20150170A7 CU 20150170 A7 CU20150170 A7 CU 20150170A7 CU P2015000170 A CUP2015000170 A CU P2015000170A CU 20150170 A CU20150170 A CU 20150170A CU 20150170 A7 CU20150170 A7 CU 20150170A7
Authority
CU
Cuba
Prior art keywords
pharmaceutical compositions
prophylaxis
prepare
compounds
treatment
Prior art date
Application number
CUP2015000170A
Other languages
English (en)
Other versions
CU24283B1 (es
Inventor
Volker Schulze
Michael BRÜNING
Detlef Stöckigt
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20150170(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20150170A7 publication Critical patent/CU20150170A7/es
Publication of CU24283B1 publication Critical patent/CU24283B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones farmacéuticas que comprenden compuestos del tipo de las triazolopiridinas sustituidas de la fórmula general (I), que son como se los describe y se los define en la presente. Métodos para prepararlas. Su uso en el tratamiento o la profilaxis de determinadas enfermedades
CUP2015000170A 2013-06-06 2014-06-05 Composiciones farmacéuticas CU24283B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170754 2013-06-06
PCT/EP2014/061711 WO2014195408A1 (en) 2013-06-06 2014-06-05 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CU20150170A7 true CU20150170A7 (es) 2016-03-31
CU24283B1 CU24283B1 (es) 2017-11-07

Family

ID=48569985

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2015000170A CU24283B1 (es) 2013-06-06 2014-06-05 Composiciones farmacéuticas

Country Status (35)

Country Link
US (1) US20160120854A1 (es)
EP (1) EP3003381B1 (es)
JP (1) JP2016523229A (es)
KR (1) KR20160018513A (es)
CN (1) CN105263526A (es)
AP (1) AP2015008890A0 (es)
AR (1) AR096469A1 (es)
AU (1) AU2014276870A1 (es)
BR (1) BR112015030292A2 (es)
CA (1) CA2914439A1 (es)
CL (1) CL2015003535A1 (es)
CR (1) CR20150641U (es)
CU (1) CU24283B1 (es)
CY (1) CY1119666T1 (es)
DK (1) DK3003381T3 (es)
DO (1) DOP2015000295A (es)
EA (1) EA201501177A1 (es)
ES (1) ES2652149T3 (es)
HK (1) HK1219906A1 (es)
HR (1) HRP20171888T1 (es)
HU (1) HUE034883T2 (es)
LT (1) LT3003381T (es)
MA (1) MA38642A1 (es)
NI (1) NI201500172A (es)
NO (1) NO3003381T3 (es)
PE (1) PE20152028A1 (es)
PH (1) PH12015502703A1 (es)
PL (1) PL3003381T3 (es)
PT (1) PT3003381T (es)
RS (1) RS56666B1 (es)
SG (1) SG11201509114TA (es)
SI (1) SI3003381T1 (es)
TN (1) TN2015000524A1 (es)
UY (1) UY35600A (es)
WO (1) WO2014195408A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509858QA (en) * 2013-06-11 2015-12-30 Bayer Pharma AG Prodrug derivatives of substituted triazolopyridines
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030212102A1 (en) * 2001-06-12 2003-11-13 Koretke Todd W Novel solid dispersion compositions
CA2578442A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation Pharmaceutical compositions comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide for the treatment of cancer
CN101125124B (zh) * 2006-08-16 2011-04-20 沈阳药科大学 一种亲脂性药物固体分散体的制备方法
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
UA112096C2 (uk) * 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CN102512358B (zh) * 2011-12-16 2013-04-10 南京农业大学 家畜用利福昔明阴道栓剂及其制备方法
CN102626384A (zh) * 2012-04-12 2012-08-08 临沂大学 一种姜黄素混悬剂及其制备方法

Also Published As

Publication number Publication date
ES2652149T3 (es) 2018-01-31
NO3003381T3 (es) 2018-02-10
TN2015000524A1 (en) 2017-04-06
PE20152028A1 (es) 2016-02-07
JP2016523229A (ja) 2016-08-08
CU24283B1 (es) 2017-11-07
KR20160018513A (ko) 2016-02-17
NI201500172A (es) 2016-01-06
RS56666B1 (sr) 2018-03-30
HUE034883T2 (hu) 2018-03-28
AU2014276870A1 (en) 2015-11-19
SG11201509114TA (en) 2015-12-30
AP2015008890A0 (en) 2015-11-30
US20160120854A1 (en) 2016-05-05
EA201501177A1 (ru) 2016-06-30
CY1119666T1 (el) 2018-04-04
EP3003381B1 (en) 2017-09-13
PH12015502703A1 (en) 2016-03-14
EP3003381A1 (en) 2016-04-13
PL3003381T3 (pl) 2018-02-28
CR20150641U (es) 2016-01-29
LT3003381T (lt) 2017-12-27
DK3003381T3 (en) 2017-12-11
AR096469A1 (es) 2015-12-30
DOP2015000295A (es) 2016-03-15
UY35600A (es) 2015-01-30
BR112015030292A2 (pt) 2017-07-25
HK1219906A1 (zh) 2017-04-21
SI3003381T1 (en) 2018-01-31
CA2914439A1 (en) 2014-12-11
WO2014195408A1 (en) 2014-12-11
CN105263526A (zh) 2016-01-20
CL2015003535A1 (es) 2016-07-08
HRP20171888T1 (hr) 2018-01-12
PT3003381T (pt) 2017-12-20
MA38642A1 (fr) 2017-10-31

Similar Documents

Publication Publication Date Title
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2017011851A2 (es) Compuestos novedosos
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2017003404A1 (es) Compuestos antibacterianos
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
BR112016023558A2 (pt) compostos úteis como imunomoduladores
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
PE20151023A1 (es) Triazolopirazinas
NI201400079A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
UY36702A (es) Piridinas sustituidas y métodos de uso
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
UY35711A (es) Bis-amidopiridinas como moduladores de la actividad de iap y sus usos como miméticos de smac
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CR20150440A (es) Nuevos derivados de piridina
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2